Current Trials and Studies
GI429: ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma – CA266-0004
Download Brochure
GI387: A Phase II Study Investigating Fruquintinib plus FOLFIRI as Second-Line Treatment for Participants with Metastatic Colorectal Cancer (FRUITFUL)
GI 441 A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
GI 444 A randomized, open-label, 3-arm Phase 3 study of precemtabart tocentecan with or without bevacizumab compared to trifluridine/tipiracil plus bevacizumab in participants with previously treated metastatic colorectal cancer (PROCEADE-CRC-03)
GI 449 A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer
To explore other clinical trial opportunities available through Sarah Cannon Research Institute, click here. Clinical trials are available to search by cancer type and zip code.[HL1]
For additional questions, feel free to contact:
Crystal Johnson
Clinical Research Coordinator, Supervisor
(573) 314-7365
Fax: 573-443-3627
[email protected]
Coby Ayers
Clinical Research Coordinator
(573) 441-3711
[email protected]
We are located at:
1705 E Broadway, Suite 100
Columbia, MO 65201
Phone: (573) 874-7800 We look forward to hearing from you and discussing how you can become a part of this important research.